Sanofi (France) (SAN.PA) Cholesterol Drug Touted as Potential $3 Billion Blockbuster
9/26/2013 7:37:43 AM
Donald Danforth isn't the only one hiring, others are hiring too! Check it out! (Isn't it tempting?)
A new cholesterol-lowering drug from Sanofi and Regeneron has the potential to become a $3-billion-dollar-plus blockbuster, according to analysts awaiting imminent late-stage trial results. The drug, dubbed alirocumab, is part of a group of biotech medicines known as PCSK9 inhibitors that offer a new way of fighting the build-up of artery-clogging fatty deposits that put millions of patients worldwide at risk of heart attacks. PCSK9 inhibitors are eyed as potentially the biggest advance in the fight against heart diseases since statin drugs such as Lipitor and Zocor, now widely available as cheap generics, were launched more than two decades ago.
Don't forget, hundreds of biopharma companies are hiring! (We know you can't resist.)